Table 1.
Hot targets and representative antibodies.
| Hot targets and representative antibodies | |||
|---|---|---|---|
| Target | Antibody therapeutics products | Antibodies in late-stage clinical studies | |
| T cell |
CTLA-4 | Tremelimumab, Ipilimumab, | Zalifrelimab, Quavonlimab, Ipilimumab biosimilar, Tuvonralimab, Erfonrilimab |
| PD-1 | Pembrolizumab, Nivolumab, Toripalimab, Tislelizumab, Sintilimab, Serplulimab, Retifanlimab, Pucotenlimab, Prolgolimab, Penpulimab, Geptanolimab (Genolimzumab), Dostarlimab, Cemiplimab (cemiplimab-rwlc), Camrelizumab, Enlonstobart, Cadonilimab, | Sasanlimab, Rulonilimab, Nofazinlimab, Finotonlimab, Cetrelimab, QL1604, zimberelimab, Tebotelimab, Iparomlimab, Ivonescimab | |
| PD-L1 | Tagitanlimab, Sugemalimab, Socazolimab, Envafolimab, Durvalumab, Cosibelimab, Avelumab, Atezolizumab, Adebrelimab | APL-502, Erfonrilimab, Bintrafusp alfa, Retlirafusp alfa | |
| CD40L | \ | Dapirolizumab pegol,dazodalibep,Letolizumab (BMS-986004),VIB4920 | |
| LAG-3 | relatlimab | Fianlimab, Favezelimab, Tebotelimab, TSR-033, BI-754111, LAG525, GSK2831781, INCAGN2385-101, DNV3, MK-4280 | |
| OX40 | \ | Rocatinlimab, Ivuxolimab, PF-04518600, IBI101, BMS-986178, MEDI-6383, ABBV-368 | |
| TIGIT | \ | Vibostolimab, Tiragolumab, Ociperlimab, Domvanalimab, etigilimab | |
| TIM-3 | \ | Sabatolimab, Cobolimab, BMS-986258, INCAGN-02390 | |
| CD27 | \ | Varlilumab, MK-5890 | |
| CD70 | \ | ARGX-110, MDX1411, SEA-CD70 | |
| BTLA | \ | icatolimab, HFB200603 | |
| GITR | \ | BMS-986156, ASP1951(PTZ-522), MEDI1873 | |
| 4-1BB | \ | ADG106, Urelumab,Utomilumab | |
| CD40 | \ | YH-003, BSI-038, CDX-1140, SEA-CD40, ADC-1013, APX005M | |
| ICOS | \ | feladilimab, MEDI-570, Vopratelimab | |
| Multispecific antibody | Cadonilimab | CDX-527,TJ-L14B/ABL503,GNC-038,ZGGS15,MGD-013,FS118,XmAb22841,RO 7121661 (RG 7769),AZD-7789,XmAb23104,GEN-1046,ND-021,GNC-035, KN046 | |
| NK cell |
CD16A | \ | AFM24, AFM12, AFM13 |
| CD16a-IL-15/CD33 | \ | GTB-3550 | |
| NKp30 | \ | CTX-8573 | |
| 5T4/CD16/NKG2D | \ | DF7001 | |
| KIR3DL-2 | \ | Lacutamab (IPH4102) | |
| NKG2A | \ | monalizumab, BMS-986315 | |
| NKp46 | \ | Cytovia,INNATE PHARMA | |
| NKp46/CD16 | \ | SAR443579, IPH62 | |
| NKp46/CD38 | \ | CYT-338 | |
| CD19/CD3 | blinatumomab | \ | |
| HER2/CD3/CD28 | \ | SAR443216 | |
| Macrophage | CD47 | \ | Letaplimab, IBI-322, magrolimab, SRF231, ALX148, AO-176 |
| SIRPα | \ | OSE-172, TTI-622, TTI-621, CC95251 | |
| CSF-1R | \ | emactuzumab, PLX-3397, PLX-7486, ARRY-382, AMG820, FPA008 | |
| TREM1 | \ | PY-159 | |
| TREM2 | \ | AL-002, PY-314 | |
| PSGL-1 | \ | SSGJ-617 | |
\, None.